Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — HGF Potentiator
What is Dihexa?
Dihexa is a small molecule derived from angiotensin IV that potentiates HGF (hepatocyte growth factor) signaling at the MET receptor — a pathway critical for synaptogenesis (new synapse formation). Developed at Washington State University, it shows remarkable potency in animal models of cognitive decline, estimated to be 10 million times more potent than BDNF in promoting synaptic growth.
Dihexa binds to HGF and facilitates its binding to the MET receptor on neurons, triggering synaptogenesis — the formation of new synaptic connections. Unlike compounds that increase BDNF or NGF, Dihexa works downstream at the synaptic growth stage. The resulting synaptic density increases support memory consolidation, learning, and cognitive resilience. It crosses the blood-brain barrier when administered orally or transdermally.
Research Evidence
Animal studies show remarkable improvement in cognitive tasks associated with new synapse formation. Potency estimated at 10 million times BDNF in promoting synaptic growth. No animal safety concerns at tested doses.
Growing community use as a potent nootropic. Subjective reports emphasize enhanced memory consolidation, verbal fluency, and cognitive clarity. No published human clinical trials.
Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
This compound does not require reconstitution — it is available as a pre-mixed injectable or oral formulation.
Frequently Asked Questions
How potent is Dihexa compared to other nootropic peptides?
Dihexa is estimated to be approximately 10 million times more potent than BDNF in animal synaptogenesis assays — by far the most potent nootropic compound in community use. This extreme potency means dose precision matters significantly and long-term human safety data is completely absent.
Can Dihexa be used topically?
Yes. Dihexa is highly lipophilic and crosses the skin barrier effectively. Transdermal application (dissolved in DMSO or a skin cream) is a common route used in community protocols, and may provide more consistent CNS delivery than oral dosing.
References
- [1]McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154.
- [2]Benoist CC, Wright JW, Bhatt DL, et al. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J Pharmacol Exp Ther. 2011;339(1):35-44.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article